From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2017 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“已获批准、指定、列入、合格、注册、报销或预先授权的选择”,从而进入买家自身的采购、报销、处方集、规格、采购、网络、目录或计划系统,使得未来业务中相当一部分可以无需每次单独销售事件即可获得,并且管理层传达这种准入状态是新的,大部分量能尚未反映在报告结果中。 在记录中,管理层提到了几个创新和渠道举措: - 在湿剃领域,推出了首个直接面向消费者的网站 schickhydro.com,以及 Hydro Connect 产品,该产品兼容吉列手柄。 - 在中国通过天猫合作伙伴推出 Hydro Connect。 - 在意大利和中欧多个市场推出 Hydro Connect 进入零售渠道。 这些是具体的分销和渠道进入,但需要判断是否属于“已批准、指定、列入”等系统性的准入,而不仅仅是普通的销售关系。管理层提到“我们推出了首个直接面向消费者的网站”,以及“通过天猫合作伙伴推出”,这些是新的渠道,但并未明确说明这些渠道是“已批准、指定”等,而是普通的销售渠道。此外,管理层没有明确说这些渠道的准入是新的,且大部分量能尚未反映。管理层提到“这些只是开始”,但并未具体说明这些渠道带来的业务量是否尚未反映在结果中。 另外,管理层提到“我们继续看到前所未有的品类下滑和竞争压力”,但并未提及公司被纳入任何采购系统。 因此,根据提供的记录,没有明确证据表明公司已进入某种“默认”或“预先授权”的采购路径,而只是普通的销售渠道扩展。所以答案应为 NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.